Jonathan Aschoff
Stock Analyst at Roth MKM
(0.61)
# 3,757
Out of 4,711 analysts
45
Total ratings
22.64%
Success rate
-35.39%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $1.75 | +530.37% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.49 | +147.35% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $555 → $296 | $4.41 | +6,612.02% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.55 | +1,061.29% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $1.00 | +1,600.00% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $1.44 | +3,025.00% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $2.29 | +773.36% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $21 → $11 | $0.32 | +3,365.66% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $1.67 | +2,295.21% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $0.24 | +11,814.89% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $40 | $1.26 | +3,074.60% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $7.16 | +402.79% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $24 | $0.91 | +2,537.36% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.61 | +434.76% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $4.40 | +4,445.45% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.17 | +545.16% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $450 | $0.30 | +152,442.37% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $0.77 | +933.19% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.07 | +4,730.92% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.98 | +40,778.90% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $5.12 | +642.19% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $480 | $0.18 | +270,933.31% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.84 | +5,117.39% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $4.40 | +195.45% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $1.75
Upside: +530.37%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.49
Upside: +147.35%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $555 → $296
Current: $4.41
Upside: +6,612.02%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.55
Upside: +1,061.29%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $1.00
Upside: +1,600.00%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $1.44
Upside: +3,025.00%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $2.29
Upside: +773.36%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $21 → $11
Current: $0.32
Upside: +3,365.66%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $1.67
Upside: +2,295.21%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $0.24
Upside: +11,814.89%
Mar 27, 2024
Maintains: Buy
Price Target: $12 → $40
Current: $1.26
Upside: +3,074.60%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $7.16
Upside: +402.79%
Mar 5, 2024
Maintains: Buy
Price Target: $5 → $24
Current: $0.91
Upside: +2,537.36%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $5.61
Upside: +434.76%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $4.40
Upside: +4,445.45%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.17
Upside: +545.16%
Feb 14, 2023
Maintains: Buy
Price Target: $150 → $450
Current: $0.30
Upside: +152,442.37%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $0.77
Upside: +933.19%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.07
Upside: +4,730.92%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.98
Upside: +40,778.90%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $5.12
Upside: +642.19%
Feb 12, 2021
Initiates: Buy
Price Target: $480
Current: $0.18
Upside: +270,933.31%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.84
Upside: +5,117.39%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $4.40
Upside: +195.45%